drugset
drugset / Trial / NCT02415907

Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

NCT02415907 ↗

Phase 1 Completed 6 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigating the absorption, metabolism and excretion of radio labelled single doses of idalopirdine in healthy men.

Timeline

Start
2015-04
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject [benzyl-7-14C]-idalopirdine Unknown 2.4 mbq Oral
Subject [benzyl-7-14C]-idalopirdine Unknown 120 mg Oral
Subject [ethyl-1-14C]-idalopirdine Unknown 2.4 mbq Oral
Subject [ethyl-1-14C]-idalopirdine Unknown 120 mg Oral

Indications

No indication recorded.